专利号:US-8067460-B2 优先权日:2004-10-04 标 题 :5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel 发明人:WULFF HEIKE; SANKARANARAYANAN ANANTHAKRISHNAN; HAENSEL WOLFRAM; SCHMITZ ALEXANDER; SCHMIDT-LASSEN KRISTINA 权利人:WULFF HEIKE; SANKARANARAYANAN ANANTHAKRISHNAN; HAENSEL WOLFRAM; SCHMITZ ALEXANDER; SCHMIDT-LASSEN KRISTINA; UNIV CALIFONIA 摘要:Compositions of matter comprising 5-phenoxyalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or animal subjects, including autoimmune diseases. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds may be due at least in part to potassium channel inhibition. In some embodiments, the compounds are more selective for certain potassium channels (e.g., Kv1.3 channels) than other potassium channels (e.g., Kv1.5 channels).
专利号:US-2024342119-A1 优先权日:2021-08-02 标 题:Composition for treating hypertrophic scars and keloids comprising benzhydryl thioacetamide compound as active ingredient 发明人:KIM SEONG-JIN; KIM SEON-MYUNG 权利人:CELLIONBIOMED INC 摘要:The present invention relates to a composition for treating hypertrophic scars and keloids, comprising a benzhydryl thioacetamide compound as an active ingredient. The benzhydryl thioacetamide compound inhibits cell proliferation and an increase in intracellular Ca 2+ concentration, in fibroblasts, keratinocytes and vascular endothelial cells that are involved in skin fibrosis, and inhibits the synthesis of collagen, which is the extracellular matrix, and thus has the effect of effectively treating intractable hypertrophic scars and keloids.
1: Glaser N, Chu S, Weiner J, Zdepski L, Wulff H, Tancredi D, ODonnell ME. Effects of TRAM-34 and minocycline on neuroinflammation caused by diabetic ketoacidosis in a rat model. BMJ Open Diabetes Res Care. 2022 May;10(3):e002777. doi: 10.1136/bmjdrc-2022-002777. 2: Schilling T, Eder C. TRAM-34 inhibits nonselective cation channels. Pflugers Arch. 2007 Jul;454(4):559-63. doi: 10.1007/s00424-007-0232-4. Epub 2007 Feb 23. 19(18):3515-21. 37(12):995-1002. doi: 10.1093/ajh/hpae115. 5: Stransky N, Ganser K, Quintanilla-Martinez L, Gonzalez-Menendez I, Naumann U, Eckert F, Koch P, Huber SM, Ruth P. Efficacy of combined tumor irradiation and KCa3.1-targeting with TRAM-34 in a syngeneic glioma mouse model. Sci Rep. 2023 Nov 23;13(1):20604. doi: 10.1038/s41598-023-47552-4.
合成参考文献
参考文献:10.1038/jcbfm.2011.101 摘要:Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2011 Dec;31(12):2363–74.